Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313

• Date : 2022-09-14
• 21    
  1

Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD

• Date : 2022-09-14
• 16    
  0

Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study

• Date : 2022-09-14
• 15    
  0

Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study

• Date : 2022-09-14
• 9    
  0

Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801

• Date : 2022-09-14
• 8    
  0

Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study

• Date : 2022-09-14
• 8    
  0

Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study

• Date : 2022-09-14
• 6    
  0

18ème Biennale Monégasque de Cancérologie

• Date : 2028-02-01
• 973    
  0

11ème Monaco Age Oncologie 2027

• Date : 2027-01-27
• 969    
  0

2ème Biennale des Infirmières Spécialisées en Oncologie

• Date : 2027-01-26
• 878    
  0

ESMO Immuno-Oncology Congress 2026

• Date : 2026-12-14
• 2587    
  0

Society of Urologic Oncology Annual Meeting

• Date : 2026-12-02
• 1828    
  0